Efficacy and Safety of Lisdexamfetamine Dimesylate and Atomoxetine in the Treatment of Attention-Deficit/Hyperactivity Disorder: a Head-to-Head, Randomized, Double-Blind, Phase IIIb StudyRegina Dittmann, David Coghill, Paul Hodgkins et al.|CNS Drugs|2013Cited by 88
Economic burden associated with chronic constipation in Sweden: a retrospective cohort studySara Bruce Wirta, Alain Joseph, Paul Hodgkins|ClinicoEconomics and Outcomes Research|2014Cited by 28
Clinical outcomes by supplemental oxygen use in remdesivir-treated, hospitalised adults with COVID-19Nadir Arber, F. Raffi, Pallav L. Shah et al.|Infectious Diseases Now|2023Cited by 1
Weight-related safety outcomes of lisdexamfetamine dimesylate in children and adolescents with attention-deficit/hyperactivity disorderMichel Lecendreux, David Coghill, Alessandro Zuddas et al.|European Child & Adolescent Psychiatry|2013Cited by 0